The primary aim of the trial is to determine whether the new combination improves the time patients live without their disease getting worse and, for a portion of the study, also extends overall survival compared with standard care.

Participants are randomly assigned to receive either the experimental medicines or the usual therapy, with treatment given in repeated cycles of intravenous infusions and oral tablets over several months. Throughout the study, doctors monitor tumor size using imaging scans evaluated by the criteria called RECIST 1.1, record how long the disease stays stable (progression free survival), note the length of life from start of treatment (overall survival), and assess how many patients experience tumor shrinkage (objective response rate). Safety is evaluated by tracking side effects, vital signs, laboratory tests and heart rhythm recordings.

Participants will receive a single dose of the tracer, then undergo the scan a short time later. The images are compared with the findings from tissue analysis after surgery or with routine follow‑up scans to confirm whether the cancer has spread. The study follows each participant from the initial scan through surgery and a one‑year follow‑up period to collect the needed information.

The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

The study is for people with stomach cancer that may still be treated with the goal of cure. After the standard tests already used for staging, the participant receives the 68Ga-FAPI-46 injection and then has a PET-CT scan. The doctors then compare the new scan with the usual test results to see whether the understanding of how far the cancer has spread changes in a helpful way. This includes checking the TNM classification, which is a common way to describe the size of the tumor, whether nearby lymph nodes are involved, and whether the cancer has spread to other parts of the body.

The study also looks at whether the scan changes the planned treatment, such as surgery, chemotherapy, or radiotherapy. It is focused on how well the scan can help with the first staging of the disease, including the usual surgical look inside the abdomen when that is part of care. The study uses several forms of the same product for making the radioactive substance, including GalliaPharm and Galliad, but the imaging substance used in the scan is 68Ga-FAPI-46.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

The investigation uses a specialized technique known as PET, which is a type of scan used to visualize how certain substances work inside the body. During the process, the substance [68Ga]BED003 is administered through an intravenous injection, meaning it is delivered directly into a vein. This substance is designed to target a specific protein found in certain tumor environments to help create clearer images. The scans are often combined with a computed tomography, which uses X-rays to create detailed pictures of the body’s internal structures.

Participants in the study will undergo imaging to see how well the new substance can identify cancer cells within the peritoneum, which is the thin layer of tissue that lines the inner wall of the abdomen and covers most of the organs. The study will monitor how the imaging agent behaves over time and check for any side effects. The goal is to determine if this new method can provide more accurate information about the presence and location of these cancers compared to standard medical practices.

The purpose of the study is to compare these two sedation approaches to see which one works better and is safer during endoscopic ultrasound procedures. Patients participating in the study will be randomly assigned to receive either remimazolam or propofol for their sedation. The study will look at whether patients experience any problems with their heart or breathing during the procedure, such as low oxygen levels, changes in blood pressure, irregular heartbeat, or changes in heart rate. The medications will be given through a vein, and remimazolam can be given up to a total of 33 milligrams while propofol will be given at a rate based on the patient’s weight.

The study will also examine other aspects of the sedation experience, including how satisfied patients and doctors are with the quality of sedation, how long it takes to start the procedure, how quickly patients wake up afterward, how much time is spent in the recovery area, and whether any additional medications are needed. The study will track if patients experience pain when the medication is injected, whether they need to stay in the hospital, and whether any breathing support is required. Information will also be collected about the costs of the different sedation approaches, including the price of medications, staff time, and how long the procedure rooms are occupied.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The purpose of this study is to find out whether tislelizumab given as an injection under the skin reaches the same levels in the body as when it is given through a vein, and to see if the injection under the skin is as safe and effective as the intravenous method. The study will measure the amount of medication in the blood at different times and compare the results between the two groups. Researchers will also look at how well the treatment works by checking whether tumors shrink or stop growing, how long patients live without their cancer getting worse, and how long the treatment keeps working.

During the study, patients will receive tislelizumab in one of the two ways mentioned, along with chemotherapy, as their first treatment for this type of advanced cancer. The treatment can continue for up to 24 months. Throughout the study, doctors will monitor patients for any side effects and collect information about how the cancer responds to treatment. Patients will need to provide tumor tissue samples for testing, and the study will also check whether the body develops any immune responses against the medication.

Participants in this study will undergo a gastrectomy, a surgical procedure to remove part or all of the stomach. Around the time of the surgery, the medication will be administered to target the cancer cells. The study will monitor how the body processes the drugs and look for any side effects or complications that may occur during or after the treatment process.

Participants may receive a combination of the study drug pumitamig (also referred to as BNT327) and chemotherapy. The chemotherapy medications involved include oxaliplatin, fluorouracil, and capecitabine, sometimes used alongside calcium folinate. In the first part of the study, two different doses of pumitamig are tested to see which one works best. In the second part, the more effective dose is compared to a standard treatment consisting of nivolumab and chemotherapy.

The study is conducted in stages. Initially, the goal is to determine which dose of the new medicine is most effective at controlling tumor growth while minimizing side effects. Following this, the selected dose is evaluated to see if it can extend progression-free survival, which is the length of time a patient lives with the disease without it getting worse, and overall survival, which is the total length of time a patient remains alive.

During the study, participants will receive an intravenous injection, meaning the substance is delivered directly into a vein. After the injection, the imaging process will be performed to look for signs of cancer in the abdominal area. The effectiveness of the GEH300079 (68Ga) injection will be compared to standard imaging methods currently used in medical practice to see if this new method provides more accurate information about the presence and location of cancer cells.

The purpose of the study is to find out if this treatment is safe and to determine the best dose that patients can tolerate. The study will also look at whether the treatment helps to control or shrink the tumors. Patients in this study must have tumors that show the presence of the CLDN6 protein and must have cancer that has spread or cannot be removed by surgery. The treatment is given through an infusion into a vein. During the study, doctors will closely monitor patients for any side effects and will measure how the tumors respond to the treatment using imaging scans or blood tests that measure certain markers in the blood.

The study will follow patients for several years to understand the long-term effects of the treatment and how well it works over time. Doctors will collect blood samples to measure changes in the immune system and to see how long the modified immune cells stay in the body. The study will test different doses of the cell therapy and the vaccine to find the most appropriate amount to use in future studies. Some patients will receive treatment made using a manual process while others will receive treatment made using an automated process to compare whether both methods work similarly.

The study involves people whose tumors test negative for a protein called HER2 but positive for two other proteins called CLDN18.2 and PD-L1. During the study, participants will receive either zolbetuximab or a placebo along with pembrolizumab and chemotherapy through intravenous infusions. Some chemotherapy medications will be given as tablets to take by mouth.

Researchers will track how long participants live, whether their cancer grows or spreads, and how their tumors respond to treatment. They will also monitor participants for any side effects from the treatment combination. The study will check blood samples to measure drug levels and test for the body’s immune response to the medications.

The purpose of this study is to determine if adding domvanalimab and zimberelimab to standard chemotherapy improves how long patients can live without their cancer getting worse. Domvanalimab and zimberelimab are types of immunotherapy medications that help the body’s immune system fight cancer cells. The study is designed for patients whose cancer has continued to grow during or after receiving previous chemotherapy treatments.

The treatment will be given through intravenous infusion, which means the medications are delivered directly into the bloodstream through a vein. Patients will receive treatment for up to 24 months, with regular medical check-ups to monitor their health and assess how well the treatment is working. During the study, doctors will take images of the cancer using scans to measure any changes in tumor size.

The purpose of this research is to understand how safe AZD4360 is and how well it works in treating these types of cancer. The study will also examine how the medication moves through the body over time. The medication will be given to patients whose cancer has a specific characteristic called CLDN18.2 expression and who have already received at least one previous treatment for their cancer.

This is a combined Phase 1 and Phase 2 study, which means it will first determine the safest dose of the medication and then test how effective it is at treating these cancers. During the study, participants will receive AZD4360 and undergo various medical assessments to monitor their health and the medication’s effects. The treatment will continue as long as patients are benefiting from it and not experiencing unacceptable side effects.

Participants in the study will undergo the [18F]AlF-FAPI-74 PET/CT scan, which is a non-invasive way to look at the whole body and check for cancer spread. This scan might reduce the need for a procedure called laparoscopy, where a small camera is inserted into the abdomen to look at the stomach and surrounding areas. The study aims to find out if the scan can help doctors make better decisions about treatment, such as whether surgery is necessary or if other treatments might be more appropriate.

The study will also look at how the scan affects the overall treatment plan, including any changes in surgery plans or additional tests that might be needed. It will assess the impact on patients’ quality of life and any extra burden from undergoing the scan. The goal is to improve the way advanced gastric cancer is staged and treated, potentially leading to fewer unnecessary surgeries and better outcomes for patients.

The purpose of the study is to evaluate how well the new combination works as a first-line treatment for patients with this type of cancer. Participants in the study will be randomly assigned to receive either the new combination or the standard treatment. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure the results are unbiased. The study will take place over a period of time, with regular assessments to monitor the progress and health of the participants.

Throughout the study, researchers will focus on key outcomes such as progression-free survival, which measures how long patients live without the cancer getting worse, and overall survival, which measures how long patients live overall. The study will also look at the safety of the treatments and any side effects that may occur. By the end of the study, the goal is to determine if the new treatment combination offers a better option for patients with this type of cancer.

Participants in the study will receive the iron treatment before their surgery. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will monitor the number of patients who need blood transfusions, as well as their hemoglobin levels, which is a measure of the amount of oxygen-carrying protein in the blood, and any complications that occur after surgery. The study will also look at the quality of life of the participants after their surgery.

The trial is expected to continue for several years, allowing researchers to gather enough information to determine the effectiveness of the iron treatment in improving outcomes for patients with gastric cancer. The results of this study could help improve the care and recovery of patients undergoing surgery for this type of cancer.

The purpose of the study is to evaluate how well the 68Ga-FAPI-46 PET imaging works in detecting gastrointestinal cancers. Participants in the study will undergo this imaging process, which is designed to provide clear pictures of the cancerous regions. The study will compare the results of this new imaging method with previous standard imaging techniques to see if it offers better detection of cancer locations.

Throughout the study, the safety of the 68Ga-FAPI-46 PET imaging will be monitored, including any side effects that may occur. The study will also assess how the imaging results might influence treatment decisions made by doctors. This research aims to improve the understanding of how effective this imaging method is in identifying and managing gastrointestinal cancers.

The trial will compare this new treatment method to the current standard treatment, which is systemic palliative chemotherapy. Two chemotherapy drugs will be used in the study: docetaxel, marketed as TAXOTERE, and oxaliplatin, marketed as Oxaliplatine Accord. These drugs are administered as a solution for infusion, meaning they are given directly into the bloodstream through a vein.

The main goal of the study is to see if the new treatment method can improve the overall survival of patients compared to the standard treatment. Participants will undergo the treatment and be monitored for their response to the therapy, any side effects, and their quality of life. The study will also look at how the drugs are processed in the body and their ability to penetrate cancerous tissues. The trial is expected to continue until December 2025.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

The study will involve participants receiving either AZD0901 or one of the standard treatments, which may include medications like Docetaxel, Irinotecan, Paclitaxel, Lonsurf (which contains trifluridine and tipiracil), or Cyramza (which contains ramucirumab). These treatments are typically administered as solutions for infusion, meaning they are given directly into the bloodstream through a vein, except for Lonsurf, which is taken as a tablet by mouth.

The purpose of the study is to determine if AZD0901 is more effective than the standard treatments in improving the health outcomes of participants. The trial will be conducted over several years, and participants will be monitored closely to assess the treatment’s impact on their cancer and overall health. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments being studied. The study will help researchers understand how well AZD0901 works and its safety profile compared to existing cancer therapies.

The treatment involves surgical removal of the stomach (gastrectomy) followed by HIPEC in one group of patients. HIPEC is a procedure where heated chemotherapy drugs are circulated directly in the abdominal cavity. The medications used during HIPEC include oxaliplatin, fluorouracil, and calcium levofolinate. These drugs are administered through the veins or directly into the abdominal cavity during the procedure.

The study will monitor patients’ overall survival, cancer recurrence, side effects, and quality of life. Half of the patients will receive surgery with HIPEC, while the other half will receive surgery alone. The treatment approach each patient receives is determined randomly, similar to flipping a coin.

The purpose of the study is to see if the new combination of domvanalimab and zimberelimab with chemotherapy can help people live longer compared to the treatment with nivolumab and chemotherapy. Participants in the study will be randomly assigned to receive either the new combination treatment or the nivolumab treatment. The study will last for up to 24 months, during which participants will receive their assigned treatment and be monitored regularly by the study team. The study will also look at how the treatments affect the participants’ quality of life and any side effects they may experience.

In addition to the main goal of comparing how long participants live with each treatment, the study will also look at other important factors. These include how long it takes for the cancer to start growing again, how many participants experience a reduction in their cancer size, and how long these reductions last. The study will also monitor any side effects or adverse events that participants may experience during the trial. This information will help researchers understand the safety and effectiveness of the new treatment combination.

The purpose of this research is to evaluate how well the tumor responds to treatment before surgery. The treatment is given both before and after surgery, which is known as perioperative treatment. During surgery, doctors will examine the tumor tissue to determine if any cancer cells remain after the initial treatment phase.

Patients will receive the combination of medications over multiple treatment cycles. The medications are given as solutions that are diluted and then infused into a vein. The treatment period may last up to 16 weeks, during which patients will be monitored for how well the treatment works and any side effects that may occur.

Participants in the study will receive treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor the participants over time to assess how well they tolerate the treatment and to observe any changes in their cancer. The trial will also look at how the body processes AZD0901 and whether the immune system reacts to it. The study aims to gather information on the overall survival of participants, how long they live without the cancer getting worse, and how long any positive response to the treatment lasts.

Throughout the study, researchers will collect data on the size of the tumors and any changes that occur. They will also investigate the relationship between certain genetic or protein markers in the tumors and the effectiveness of the treatment. This information will help determine if AZD0901 could be a beneficial treatment option for patients with these types of cancers. The study is expected to continue until 2027, with recruitment of participants starting in late 2024.

The treatment plan combines standard chemotherapy given through a vein with a special procedure where irinotecan, an anti-cancer medication, is heated and delivered directly into the abdominal cavity. This heated chemotherapy treatment is given before the surgery to remove the stomach. Patients will receive at least three rounds of regular chemotherapy before the heated chemotherapy procedure.

During the study, doctors will monitor how well the treatment prevents the cancer from returning to the abdomen’s lining. They will also track overall patient recovery and well-being using quality of life surveys. The treatment approach being studied may offer a new way to treat stomach cancer patients who have a high risk of the cancer spreading to the abdominal cavity.

The study will use two different treatment approaches. Some patients will receive nivolumab alone, while others will receive a combination of nivolumab and ipilimumab. Both medications are given through an intravenous infusion, which means they are delivered directly into a vein. The medications being tested are designed to boost the immune system’s ability to detect and destroy cancer cells.

During the study, doctors will monitor how patients respond to the treatment and track any side effects that may occur. The study will look at whether tumors shrink or stop growing in response to the treatment, and how long patients survive without their cancer getting worse. This research may help develop new treatment options for patients with these types of advanced cancers.

The purpose of this research is to determine if using zanidatamab with chemotherapy, either alone or together with tislelizumab, works better than the current standard treatment of trastuzumab with chemotherapy. Zanidatamab and tislelizumab are new medications that work by helping the body’s immune system fight cancer cells. During treatment, patients may also receive loperamide, a medication that helps control diarrhea which can occur as a side effect of treatment.

Participants in this study will be randomly assigned to receive either the new treatment combination or the standard treatment. The medications will be given through an intravenous infusion (delivered directly into a vein), while some medications will be taken by mouth. The study treatment may continue for up to 756 days, depending on how well it works and how well it is tolerated by patients.

Participants in the study will receive the treatment intravenously, which means the medication will be given through a vein. The study will take place over a period of time, during which patients will receive the combination of Avelumab and chemotherapy drugs. The researchers aim to determine if this combination can lead to a complete response, meaning no remaining cancer cells, in the resected (surgically removed) cancer tissue. The study will also look at other outcomes, such as overall survival and disease-free survival, to understand the long-term effects of the treatment.

The trial is designed to provide valuable information on whether this new combination of treatments can offer better results compared to traditional chemotherapy alone. By participating in this study, researchers hope to gather data that could lead to improved treatment options for patients with Gastric cancer and Gastroesophageal Junction cancer. The study is conducted under strict guidelines to ensure the safety and well-being of all participants.

Participants in the study will receive pembrolizumab as part of their treatment plan. The study will take place over a period of time, during which patients will receive the medication and be monitored by healthcare professionals. The goal is to see how well the treatment works in reducing or eliminating the cancer cells. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of pembrolizumab. The study will also look at the safety of the treatment and any potential side effects that may occur.

Throughout the study, participants will have regular visits with their healthcare team to track their progress and ensure their well-being. The study aims to provide valuable information on the effectiveness of pembrolizumab in treating these specific types of cancers, which could lead to improved treatment options for patients in the future. The study is expected to continue until 2029, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment.

The purpose of this study is to determine the safety and effectiveness of combining BOLD-100 with FOLFOX chemotherapy in treating these types of cancers. The study is conducted in two parts. In the first part, different dose levels of BOLD-100 will be tested to find the safest and most appropriate dose. In the second part, the selected dose will be given to more patients to further study how well the treatment works.

During the study, participants will receive BOLD-100 and FOLFOX through an intravenous line (a small tube inserted into a vein). The medications will be given according to a specific schedule determined by the healthcare team. Throughout the treatment, patients will have regular check-ups to monitor their health and how well the treatment is working.

The purpose of the study is to explore the safety and feasibility of these medications when given before surgery to remove the cancer. Patients will receive these treatments over a period of time before their surgery. The study will monitor how the body responds to the medications and any side effects that may occur. Some patients will receive a placebo, which is a substance with no active medication, to compare the effects of the actual medications.

Throughout the study, patients will undergo various tests and procedures to assess the impact of the treatment on their cancer. This includes checking how the cancer responds to the treatment and any changes in the immune system. The study aims to gather information on how well these treatments work together and their safety for patients with gastric and gastro-esophageal junction cancer.

The purpose of this study is to see if the combination of Durvalumab and FLOT chemotherapy, followed by additional Durvalumab treatment, can improve outcomes for patients with resectable gastric or gastroesophageal junction cancer. “Resectable” means that the cancer can be surgically removed. The study will be conducted in phases, starting with treatment before surgery (neoadjuvant) and continuing after surgery (adjuvant). Participants will be randomly assigned to receive either the active treatment or a placebo, and neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This is known as a double-blind study.

The study will last for a period of up to 18 months, during which participants will receive the treatments and be monitored for their health and response to the treatment. The main goal is to assess event-free survival, which means the length of time participants live without the cancer getting worse or coming back. Secondary goals include overall survival and the rate of complete response to the treatment. This study aims to provide valuable information on the effectiveness of Durvalumab in combination with FLOT chemotherapy for treating gastric and gastroesophageal junction cancers.

The purpose of the study is to see if the combination of Bemarituzumab and chemotherapy can improve the overall survival of patients with this type of cancer. Participants in the study will receive either the new treatment or the placebo, and their health will be monitored over time to assess the treatment’s effectiveness. The study will involve regular check-ups and assessments to track the progress of the disease and any side effects from the treatment.

Throughout the study, participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The trial aims to provide valuable information on whether this new treatment can offer better outcomes for patients with Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s impact.

The purpose of the study is to determine if adding bemarituzumab to standard chemotherapy and nivolumab treatment improves survival for patients with previously untreated advanced stomach cancer. The medications are given through intravenous infusion, except for capecitabine which is taken by mouth. The study is conducted in two parts: a smaller initial phase to evaluate safety, followed by a larger phase to compare the effectiveness of the treatments.

During the study, participants will receive regular doses of the study medications and undergo various medical assessments. The treatment period may last for several months, depending on how well the participant responds to the therapy. Doctors will monitor participants’ health status, check for side effects, and evaluate how well the cancer responds to treatment throughout the study period.

The purpose of the study is to assess the safety and tolerability of these treatments, which means checking for any side effects and determining how well patients can handle the medications. The study will also gather preliminary information on how effective these treatments are in managing the disease. Participants will receive the medications in different doses and combinations to find the most effective and safest way to use them. The trial will also explore if a more convenient dosing schedule can be established for patients.

Throughout the study, participants will be monitored for any adverse events, which are unwanted effects that may occur during treatment. The trial will also measure how the body processes the medications, including how long they stay in the body and how they are eliminated. The study will continue until the estimated end date in 2026, with the goal of providing valuable information on the potential benefits of Relatlimab and Nivolumab for treating advanced solid tumors.

The purpose of this study is to see which treatment option helps patients live longer. Participants in the study will be randomly assigned to receive either the new combination of botensilimab and balstilimab or the standard treatment with FOLFOX/XELOX and nivolumab. The study will last for a period of up to 24 months, during which patients will receive their assigned treatment and be monitored regularly. The treatments are given through an IV infusion, which means they are administered directly into the bloodstream through a vein. Some patients may also receive a placebo, which is a substance with no active drug, to help compare the effects of the treatments more accurately.

Throughout the study, doctors will closely monitor the patients’ health and any side effects they may experience. The main goal is to determine which treatment is more effective in improving the overall survival of patients with this type of cancer. The study will also look at other factors, such as the quality of life of the patients and how their cancer responds to the treatment over time. This research is important for finding better ways to treat this challenging form of cancer and potentially improving outcomes for patients in the future.

The purpose of the study is to evaluate how effective the combination of these treatments is in improving the condition of patients with this type of cancer. The study is divided into two phases. In the first phase, the focus is on understanding the response rate of the cancer to the treatment, which means observing how much the cancer shrinks or disappears. In the second phase, the study aims to compare the overall survival of patients receiving the new combination of treatments to those receiving a standard treatment of ramucirumab and paclitaxel.

Participants in the study will receive the treatment over a period of time, and their health will be monitored closely to observe any changes in their cancer and to check for any side effects. The study will also look at how the body processes the new medication, Evorpacept, and whether it triggers any immune response. The trial is expected to continue until 2028, providing valuable information on the potential benefits and risks of this new treatment approach for patients with advanced gastric cancer.